Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET

Company Participants

David Nakasone - Head, Investor Relations
Bobby Azamian - Chairman and CEO
Aziz Mottiwala - Chief Commercial Officer
Jeff Farrow - Chief Financial Officer and CSO
Sesha Neervannan - Chief Operating Officer

Conference Call Participants

Tim Lugo - William Blair
Pavan Patel - BofA
Dennis Kennedy - LifeSci Capital
Talani Usman - Goldman Sachs
Frank Brisebois - Oppenheimer
Michaela Diverio - Barclays
Eddie Hickman - Guggenheim Securities

Operator

Good afternoon. And welcome to the Tarsus’ Second Quarter 2024 Financial Results Conference Call. As a reminder, this call is being recorded.

At this time, I would like to turn the call over to David Nakasone, Head of Investor Relations, to lead off the call. David, you may begin.

David Nakasone

Thank you. Before we begin, I encourage everyone to go to the Investor section of the Tarsus’ website to view the earnings release and related materials we will be discussing today. Joining me on the call this afternoon are Bobby Azamian, our Chief Executive Officer and Chairman; Aziz Mottiwala, our Chief Commercial Officer; Jeff Farrow, our Chief Financial Officer and Chief Strategy Officer; and joining us for the question-and-answer session, Sesha Neervannan, our Chief Operating Officer.

I’d like to draw your attention to Slide 3, which contains our forward-looking statements. During this call, we will be making forward-looking statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to consult the risk factors contained in our SEC filings for additional detail.

With that, I will turn the call over to Bobby.

Bobby Azamian

Good afternoon, everyone, and thank you for joining us. I am excited to share yet another quarter of impressive results as we continue to exceed launch expectations for XDEMVY, including our own. This call is particularly special as we have just surpassed the one-year mark of XDEMVY being the first and only FDA-approved therapy for the treatment of Demodex blepharitis or DB for short.

It was an important opportunity to reflect on one of the most transformative moments in Tarsus us history, while also looking forward to redoubling our efforts in this next phase of the XDEMVY launch.

With just three full launch quarters under our belt, we are well on our way to creating what we believe will be one of the largest categories in eye care, based on three key metrics. The number of patients we are serving, the speed with which eye care providers or ECPs have adopted XDEMVY, and the exceptional high-quality payer coverage we have secured to-date.